4.6 Review

Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension

期刊

AMERICAN JOURNAL OF MEDICINE
卷 125, 期 1, 页码 14-22

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2011.05.024

关键词

Hypertension

资金

  1. Novartis
  2. Sanofi-Aventis
  3. AstraZeneca
  4. Novo Nordik
  5. Dexon Israel
  6. Teva Israel Intercure
  7. Bristol-Myers Squibb
  8. Daiichi Sankyo
  9. Neurim Pharmaceuticals Ltd, Israel
  10. Boehringer Ingelheim, Forest

向作者/读者索取更多资源

A myriad variety of therapeutic agents or chemical substances can induce either a transient or persistent increase in blood pressure, or interfere with the blood pressure-lowering effects of antihypertensive drugs. Some agents cause either sodium retention or extracellular volume expansion, or activate directly or indirectly the sympathetic nervous system. Other substances act directly on arteriolar smooth muscle or do not have a defined mechanism of action. Some medications that usually lower blood pressure may paradoxically increase blood pressure, or an increase in pressure may be encountered after their discontinuation. In general, drug-induced pressure increases are small and transient: however, severe hypertension involving encephalopathy, stroke, and irreversible renal failure have been reported. The deleterious effect of therapeutic agents is more pronounced in patients with preexisting hypertension, in those with renal failure, and in the elderly. Careful evaluation of a patient's drug regimen may identify chemically induced hypertension and obviate unnecessary evaluation and facilitate antihypertensive therapy. Once chemical-induced hypertension has been identified, discontinuation of the causative agent is recommended, although hypertension can often be managed by specific therapy and dose adjustment if continued use of the offending agent is mandatory. The present review summarizes the therapeutic agents or chemical substances that elevate blood pressure and their mechanisms of action. (C) 2012 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2012) 125, 14-22

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据